JPRN-jRCT2041210125进行中（未招募）4 期
Crizotinib Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Crizotinib Clinical Studies - Crizotinib Continuation Clinical Study
Kawai Norisuke0 个研究点目标入组 80 人开始时间: 2022年1月8日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 1age old 至 <= 99age old（—）
- 性别
- All
入选标准
- •*Any participant who is receiving crizotinib and deriving clinical benefit (as determined by their doctor) in a Crizotinib Study which is planned to close.
- •*Participants must agree to follow the reproductive criteria as outlined in protocol.
- •*No ongoing Grade >=3 or intolerable Grade 2 AEs considered to be related to crizotinib treatment, except for those laboratory eligibility criteria described in Inclusion below.
- •*Adequate hepatic and bone marrow function. Stable renal function for at least 14 days.
排除标准
- •*Female participants who are pregnant or breastfeeding.
- •*Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.
研究者
相似试验
已完成
2 期
An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients with Plasma Therapy-Sensitive Atypical Hemolytic-Uremic Syndrome (AHUS)10018911atypical hemolytic uremic syndromeNL-OMON33473Alexion Pharmaceuticals1
招募中
4 期
Encorafenib/binimetiib master protocol: an open-label continuation study for participants continuing from encorafenib/binimetinib clinical studies. ;Sub-study 1: An open-label study for continued treatment access for participants from the C4211001 (Array CMEK162X2201) and the C4211003 (Array-162-311, MILO) Binimetinib studies.;Sub-study 2: An open-label study for continued treatment access for participants from the C4221004 (Array CMEK162B2301, Columbus) Encorafenib and Binimetinib study;Sub-s(Maligne) solide tumoren, niet-reseceerbare huidkanker, niet-kleincellige longkankercancerNL-OMON53566Pfizer3
进行中（未招募）
1 期
An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSEEUCTR2013-001421-55-FRovartis Pharma S.A.S500
进行中（未招募）
不适用
A clinical program for patients who have completed a previous Novartis-sponsored nilotinib study and who benefit from continued nilotinib treatment as judged by the treating physiciaPatients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator.MedDRA version: 14.1Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10009700Term: CMLSystem Organ Class: 100000004864EUCTR2012-003902-28-ITovartis Farma S.p.A.300
进行中（未招募）
1 期
An clinical program for patients who have completed a previous Novartis-sponsored nilotinib study and who benefit from continued nilotinib treatment as judged by the treating physiciaEUCTR2012-003902-28-ATovartis Pharma Services AG100